Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R?2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
Type:
Grant
Filed:
July 21, 2020
Date of Patent:
July 11, 2023
Assignee:
Wake Forest University Health Sciences
Inventors:
Waldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
June 20, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The methods include, inter alia, contacting a reducing agent with engineered cysteine antibody molecules, each of the antibody molecules having at least one capped engineered cysteine residue and at least one interchain disulfide bond and reacting the reducing agent with the antibody molecules under conditions sufficient to uncap engineered cysteine residues and form cap byproducts. The method also includes removing the cap byproduct during the reduction reaction. Substantially all of the interchain disulfide bonds present in the antibody molecules prior to reduction are retained following reduction. Antibody conjugates and methods for preparing antibody conjugates using uncapped antibody preparations are also described.
Abstract: Anti-TRGV9 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
June 6, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
Type:
Grant
Filed:
April 29, 2022
Date of Patent:
May 16, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
Abstract: The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
May 9, 2023
Assignee:
Epizyme, Inc.
Inventors:
Christine Klaus, Maria Alejandra Raimondi
Abstract: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
April 25, 2023
Assignees:
THE FRANCIS CRICK INSTITUTE LIMITED, UNIVERSITY COLLEGE LONDON, CANCER RESEARCH TECHNOLOGY LIMITED
Inventors:
Charles Swanton, Nicholas McGranahan, Rachel Rosenthal
Abstract: The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c (BDCA-1)+/CD19? dendritic cells, wherein CD1c(BDCA-1)+/CD19? dendritic cells are depleted for CD1c (BDCA-1)+/CD19?/CD14+ cells.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
March 28, 2023
Assignee:
MILTENYI BIOTEC B.V. & CO. KG
Inventors:
Jolanda De Vries, Carl Figdor, Ghaith Bakdash
Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
March 21, 2023
Assignee:
SEAGEN INC.
Inventors:
Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Grant
Filed:
June 7, 2022
Date of Patent:
February 28, 2023
Assignees:
GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
Inventors:
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
Abstract: The present disclosure relates to methods and compositions for the treatment of cancer using an ACAT1 inhibitor. The cancer may be any of melanoma, lymphoma, esophageal cancer, liver cancer, head and neck cancer, bladder cancer, endometrial cancer, kidney cancer and thyroid cancer. In some embodiments, the cancer itself it not responsive directly to the ACAT1 inhibitor but is rather treated through the immune system activated by the ACAT1 inhibitor. Combination therapies are also provided, for instance in combination with an alkylating antineoplastic agent.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
February 7, 2023
Assignee:
Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.
Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
January 31, 2023
Assignees:
Duke University, Menarini Silicon Biosystems S.p.A.
Inventors:
Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
January 3, 2023
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, David M. Goldenberg
Abstract: The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units, that are constructed in a site-specific matter via ‘orthogonal’ deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.
Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
December 27, 2022
Assignee:
ALLIGATOR BIOSCIENCE AB
Inventors:
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Abstract: The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
November 22, 2022
Assignees:
BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
Inventors:
Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann